Harnessing Your Immune System For Good

Emily BurkeBiologics, Biotech Basics, Cancer, Drug Targets, Mechanism of Action, Monoclonal Antibodies

YOUR INNER IMMUNE WORKINGS What do monoclonal antibodies, CAR-T therapy, and checkpoint inhibitor treatments all have in common? They are immunotherapies, or therapies that activate the immune system to fight or prevent a disease. While an activated immune system can help save a life, an overactive immune system can attack the body it is charged with protecting. This over-activity is the … Read More

Decoding The Gut-Brain Axis

Emily BurkeBiologics, Drug Development, Drug Targets, The WEEKLY

Microbiome & Disease The biotech world is abuzz with talk of the latest microbiome startup launch Axial Biotherapeutics (Boston, MA). What caught our eye here at the WEEKLY is the company’s focus on the gut microbiome — the entire collection of microbes living in the gut — and its interplay with the brain. The connection between the gut microbiome and … Read More

Unwiring The Biology Of Fibrosis

Emily BurkeAntisense, Biologics, Clinical Trials, Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies, Small Molecule Drugs, Term of the Week, The WEEKLY

Fibrotic Disease Innovations Fibrotic diseases — organ and tissue disorders that occur as a result of the buildup of excessive scar tissue — are sounding the alarm in the biotech sector. A silent epidemic creeping up on the Western world involves non-alcoholic steatohepatitis (NASH), or liver fibrosis associated with obesity and type 2 diabetes. Left untreated, NASH can lead to liver failure. Currently, … Read More